Small non-coding RNA content in plasma-derived extracellular vesicles distinguish ataxic SCA3 mutation carriers from pre-ataxic and control subjects
Magda M. SantanaiD, Patrick SilvaiD, Maria M Pinto, Laetitia S. GaspariD, Rui Jorge NobreiD, Sónia DuarteiD, Tânia Monteiro MarquesiD, Margarida Gama‐CarvalhoiD, Cristina JanuárioiD, Inês CunhaiD, Joana Afonso RibeiroiD, Jeannette Hübener‐SchmidiD, Jon InfanteiD, Mafalda RaposoiD, Manuela Caroline Ferreira LimaiD, Héctor García‐MorenoiD, Paola GiuntiiD, Bart P.C. van de WarrenburgiD, Matthis SynofzikiD, Jennifer FaberiD, Thomas KlockgetheriD, ESMI Study Group, Luís Pereira de AlmeidaiD
Abstract
Spinocerebellar ataxia type 3 (SCA3), a neurodegenerative disorder caused by a CAG expansion in the ATXN3 gene, is the most common spinocerebellar ataxia subtype worldwide. Currently, there is no therapy to stop or prevent disease progression. Promising therapeutic strategies are emerging, but their translation into clinical practice requires sensitive and reliable biomarkers. Blood circulating extracellular vesicles constitute a promising source of biomarkers with potential to track alterations of the central nervous system due to their ability to cross the blood brain barrier. Here, we perform sequencing analysis of small RNAs from plasma-derived extracellular vesicles from SCA3 mutation carriers (10 pre-ataxic and 10 ataxic) and 12 control subjects to identify potential RNA biomarker candidates for this disease. Data showed that plasma-derived extracellular vesicles from ataxic SCA3 mutation carriers are enriched in mitochondrial, nuclear, and nucleolar RNA biotypes compared to pre-ataxic and control subjects. Moreover, ataxic mutation carriers could be discriminated from control and pre-ataxic subjects based on the miRNAs or piRNAs content, but not tRNA. Furthermore, we identified a subset of differentially expressed miRNAs and piRNAs that clearly differentiate ataxic mutation carriers from pre-ataxic and control subjects. These findings open new avenues for further investigation on the role of these RNAs in the pathogenesis of SCA3 and their potential as biomarkers for this disease.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- rAAV-Delivered Bicistronic Artificial microRNAs for Allele-Specific Silencing Improve Motor and Molecular Outcomes in Spinocerebellar Ataxia Type 3
Ana Carolina da Silva, Carina Henriques, … Luís Pereira de Almeida·bioRxiv·Oct 2, 2025
- In vivo molecular signatures of cerebellar pathology in spinocerebellar ataxia type 3
Maria do Carmo Costa, Maria Radzwion, … Gülin Öz·Movement DisordersPeer-reviewed·Jul 4, 2020
- Research on Mitochondrial DNA Mutations in Patients with SCA3/MJD
Zhen Liu, Jie Zhou, … Junling Wang·bioRxiv·Jan 18, 2017
- Autophagosome-tethering compounds selectively lower mutant ataxin-3 in preclinical models of spinocerebellar ataxia type 3
Hongyu Yuan, Zhao Chen, … Hong Jiang·bioRxiv·Oct 8, 2026
- AAV-mediated allele-specific silencing alleviates neuropathology in a novel non-human primate model of Spinocerebellar ataxia type 3
Carina Henriques, Diana Duarte Lobo, … Rui Jorge Nobre·bioRxiv·Oct 2, 2025
- Age-dependent somatic expansion of the ATXN3 CAG repeat in the blood and buccal cell DNA of individuals with spinocerebellar ataxia type 3
Ahmed M. Sidky, Ana Rosa Vieira Melo, … Darren G. Monckton·medRxiv·Mar 13, 2024